Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR.
Aortic stenosis
Survival
Transcatheter aortic valve replacement
Troponin T
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
20
08
2020
accepted:
05
10
2020
pubmed:
25
10
2020
medline:
1
10
2021
entrez:
24
10
2020
Statut:
ppublish
Résumé
Elevated pre-procedural high-sensitivity troponin T (hs-TnT) levels predict adverse outcomes in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). It is unknown whether elevated troponin levels still provide prognostic information during follow-up after successful TAVR. We evaluated the long-term implications of elevated hs-TnT levels found at 1-year post-TAVR. The study included 349 patients who underwent TAVR for severe AS from 2010-2019 and for whom 1-year hs-TnT levels were available. Any required percutaneous coronary interventions were performed > 1 week before TAVR. The primary endpoint was survival time starting at 1-year post-TAVR. Optimal hs-TnT cutoff for stratifying risk, identified by ROC analysis, was 39.4 pg/mL. 292 patients had hs-TnT < 39.4 pg/mL (median 18.3 pg/mL) and 57 had hs-TnT ≥ 39.4 pg/mL (median 51.2 pg/mL). The high hs-TnT group had a higher median N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, greater left ventricular (LV) mass, higher prevalence of severe diastolic dysfunction, LV ejection fraction < 35%, severe renal dysfunction, and more men compared with the low hs-TnT group. All-cause mortality during follow-up after TAVR was significantly higher among patients who had hs-TnT ≥ 39.4 pg/mL compared with those who did not (mortality rate at 2 years post-TAVR: 12.3% vs. 4.1%, p = 0.010). Multivariate analysis identified 1-year hs-TnT ≥ 39.4 pg/mL (hazard ratio 2.93, 95% CI 1.91-4.49, p < 0.001), NT-proBNP level > 300 pg/mL, male sex, an eGFR < 60 mL/min/1.73 m Elevated hs-TnT concentrations at 1-year after TAVR were associated with a higher long-term mortality.
Sections du résumé
BACKGROUND
BACKGROUND
Elevated pre-procedural high-sensitivity troponin T (hs-TnT) levels predict adverse outcomes in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). It is unknown whether elevated troponin levels still provide prognostic information during follow-up after successful TAVR. We evaluated the long-term implications of elevated hs-TnT levels found at 1-year post-TAVR.
METHODS AND RESULTS
RESULTS
The study included 349 patients who underwent TAVR for severe AS from 2010-2019 and for whom 1-year hs-TnT levels were available. Any required percutaneous coronary interventions were performed > 1 week before TAVR. The primary endpoint was survival time starting at 1-year post-TAVR. Optimal hs-TnT cutoff for stratifying risk, identified by ROC analysis, was 39.4 pg/mL. 292 patients had hs-TnT < 39.4 pg/mL (median 18.3 pg/mL) and 57 had hs-TnT ≥ 39.4 pg/mL (median 51.2 pg/mL). The high hs-TnT group had a higher median N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, greater left ventricular (LV) mass, higher prevalence of severe diastolic dysfunction, LV ejection fraction < 35%, severe renal dysfunction, and more men compared with the low hs-TnT group. All-cause mortality during follow-up after TAVR was significantly higher among patients who had hs-TnT ≥ 39.4 pg/mL compared with those who did not (mortality rate at 2 years post-TAVR: 12.3% vs. 4.1%, p = 0.010). Multivariate analysis identified 1-year hs-TnT ≥ 39.4 pg/mL (hazard ratio 2.93, 95% CI 1.91-4.49, p < 0.001), NT-proBNP level > 300 pg/mL, male sex, an eGFR < 60 mL/min/1.73 m
CONCLUSIONS
CONCLUSIONS
Elevated hs-TnT concentrations at 1-year after TAVR were associated with a higher long-term mortality.
Identifiants
pubmed: 33098469
doi: 10.1007/s00392-020-01759-x
pii: 10.1007/s00392-020-01759-x
pmc: PMC7907029
doi:
Substances chimiques
Biomarkers
0
Troponin T
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
421-428Références
Ann Thorac Surg. 2015 Mar;99(3):809-16
pubmed: 25633460
Eur Heart J. 2020 Aug 29;:
pubmed: 32860058
Cardiovasc Ther. 2016 Dec;34(6):385-396
pubmed: 27380819
Ann Clin Biochem. 2010 Nov;47(Pt 6):524-8
pubmed: 20926463
Am J Cardiol. 2015 May 1;115(9):1265-72
pubmed: 25863422
Eur Heart J. 2003 Jul;24(13):1231-43
pubmed: 12831818
Clin Chem Lab Med. 2005;43(11):1263-73
pubmed: 16232094
Am J Cardiol. 2015 Dec 15;116(12):1904-9
pubmed: 26602075
Neth Heart J. 2020 May;28(5):280-292
pubmed: 32189208
J Cardiovasc Surg (Torino). 2020 Feb;61(1):98-106
pubmed: 31755678
Eur Heart J. 2014 Sep 7;35(34):2312-21
pubmed: 24829362
Rev Port Cardiol. 2018 Jan;37(1):67-73
pubmed: 29317115
J Heart Valve Dis. 2014 Sep;23(5):537-44
pubmed: 25799701
J Cardiovasc Surg (Torino). 2017 Aug;58(4):624-632
pubmed: 27171329
BMJ. 2015 Mar 04;350:h910
pubmed: 25740799
JACC Cardiovasc Interv. 2017 Nov 27;10(22):2345-2346
pubmed: 29169507
Clin Res Cardiol. 2014 Jan;103(1):65-72
pubmed: 24096554
Am J Cardiol. 2015 Nov 15;116(10):1560-5
pubmed: 26428025
Int J Cardiol. 2013 Nov 5;169(3):e38-9
pubmed: 24063930
J Am Heart Assoc. 2016 Feb 19;5(2):
pubmed: 26896474
J Am Heart Assoc. 2017 Jul 14;6(7):
pubmed: 28710182
Heart Vessels. 2019 May;34(5):777-783
pubmed: 30443765
Trends Cardiovasc Med. 2017 Jul;27(5):326-333
pubmed: 28256378
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
Am J Cardiol. 2016 Dec 1;118(11):1692-1697
pubmed: 27666174
Catheter Cardiovasc Interv. 2016 Mar;87 Suppl 1:570-8
pubmed: 26856312
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Int J Cardiol. 2018 Aug 15;265:40-46
pubmed: 29885699
EuroIntervention. 2016 Apr 20;11(13):1522-9
pubmed: 25671517
Cardiovasc Interv Ther. 2020 Jul;35(3):283-290
pubmed: 31529319
Eur Heart J. 2012 Sep;33(18):2265-71
pubmed: 22745356
Am J Cardiol. 2005 Apr 15;95(8):948-54
pubmed: 15820160
Wien Klin Wochenschr. 1998;110 Suppl 3:40-51
pubmed: 9677671
Scand Cardiovasc J. 2012 Oct;46(5):278-85
pubmed: 22545649
J Am Coll Cardiol. 2012 Nov 6;60(19):1864-75
pubmed: 23062535
Am J Cardiol. 2017 Sep 1;120(5):850-856
pubmed: 28688702
JACC Cardiovasc Interv. 2013 Oct;6(10):1072-84
pubmed: 24156967
Am J Cardiol. 2011 Jul 1;108(1):88-91
pubmed: 21529731